FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have Symptomatic Plexiform Neurofibromas Not Amenable to Complete Resection By Ogkologos - March 20, 2025 537 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ReNeu study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Women in science: Cancer research pioneers – part 1 January 18, 2023 A Daily Survival Kit for Serious Illness September 8, 2021 NICE doesn’t recommend olaparib for patients with certain prostate cancers September 13, 2022 Targeted Therapy for Treating Advanced Gastrointestinal Stromal Tumors (GISTs): The ASCO... January 24, 2022 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin What Latino People Should Know About Quitting Smoking and Health Disparities:... Cancer Patients Have Been Lonelier During the COVID-19 Pandemic Woman Discovers Breast Lump in the Shower After Dropping Her Loofah,...
